Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers
about
miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human agingFeud or Friend? The Role of the miR-17-92 Cluster in TumorigenesismiR-17-92 cluster: ups and downs in cancer and agingInsights into the Regulatory Role of Non-coding RNAs in Cancer MetabolismRole of Exosomal Noncoding RNAs in Lung CarcinogenesisMicroRNAs, DNA Damage Response, and Cancer TreatmentThe miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1MicroRNAs as therapeutic targets for lung cancermiR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymesMicroRNAs As Biomarkers For Clinical Features Of Lung CancerMicroRNA in lung cancer.Effects of miR-19b overexpression on proliferation, differentiation, apoptosis and Wnt/β-catenin signaling pathway in P19 cell model of cardiac differentiation in vitro.miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancersThe regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancerMechanistic Roles of Noncoding RNAs in Lung Cancer Biology and Their Clinical ImplicationsDetection of Exosomal miRNAs in the Plasma of Melanoma Patients.MicroRNA-92a negatively regulates Toll-like receptor (TLR)-triggered inflammatory response in macrophages by targeting MKK4 kinase.Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression.The roles of microRNAs in tumorigenesis and angiogenesis.Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer.miRNAs in lung cancer: large roles for small players.MicroRNA as a novel drug target for cancer therapy.MicroRNAs and lung cancers: from pathogenesis to clinical implicationsThe microRNA-17-92 family of microRNA clusters in development and disease.microRNA regulation of cell viability and drug sensitivity in lung cancer.H2AX a promising biomarker for lung cancer: a review.miRNA expression profiles associated with diagnosis and prognosis in lung cancer.The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatmentMicroRNAs in lung cancer.New insights into lung development and diseases: the role of microRNAs.Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment.Mitochondrial miRNA (MitomiR): a new player in cardiovascular health.MicroRNA-17-5p inhibits proliferation and triggers apoptosis in non-small cell lung cancer by targeting transforming growth factor β receptor 2.Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression.miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer.Enterococcus faecalis Infection and Reactive Oxygen Species Down-Regulates the miR-17-92 Cluster in Gastric Adenocarcinoma Cell Culture.Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation.Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21.MicroRNA 17-92 expressed by a transposone-based vector changes expression level of cell-cycle-related genes.MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells.
P2860
Q24606274-99124242-4AF7-46BF-A586-4EF25C06027CQ24609213-4ABA051C-D7BC-459C-B2BE-BBE17A242841Q24617309-C1CE2B3C-AC52-4F34-AD6B-A721E2CD13AEQ26739857-E36DCA6A-FDB4-4725-AD1F-AFDCA71AA69EQ27000282-5298EA6B-E3B7-4FD0-8A3E-8FB6A6E51674Q28067062-18987310-C828-43F1-A999-0C0971484F8BQ28118639-9EA69C13-F090-4120-8CC1-E44EC957243FQ28293733-91D03C4B-B296-4538-B0B6-0FBB79B05371Q28476613-4E47F026-BF1F-4E7B-B15A-D69F7BC4E61CQ34158964-62F9B0FE-71DC-4FFB-A535-3C965DD0A544Q34256044-68D04497-30B7-40EB-9E76-02A222CE8A3AQ34601524-692D6390-039B-4E4B-812F-85658FE5F4FAQ34623368-E0963A97-158B-4F54-BA5C-ABBED0748DDEQ35813690-ACE59E91-0816-402E-B841-FA0916C0E1C2Q36125057-C2A381E3-8BAD-4AE8-87BF-187B79EE457DQ36409368-13FE275A-2AAA-4847-91FF-0917962BC84EQ36685269-E54C1BFD-001A-452F-9C15-ADA80E21A39DQ37330984-BE03C0BF-3BA5-457D-9B5E-905E5595FB0DQ37901391-D816A181-6EAB-48B9-A3A2-16A499A64889Q37902246-826ACFED-F56E-42EF-9A33-EED4D6F32595Q37932539-9872B85A-0E7E-4994-BC57-28B6F7C74B21Q37994747-B6608CDA-13E8-4D75-B169-DE20BA6B288FQ38005062-FA5246D9-FB6A-47DF-B8F9-94DF10091899Q38014608-F5BA5562-D722-475A-A8B1-CA7F5BC321C1Q38021509-25A0FCC4-A2E0-47E8-B5D7-6E648A885522Q38155902-856790D9-1B29-4BEB-A736-A5A0B2B3391EQ38186130-E92BABAC-61D6-4F99-8025-92BE4B697432Q38226821-1DC6D54C-037A-4432-A48D-54006161C9D8Q38261676-B93A065A-2921-4E54-8534-41866B6EB406Q38309155-6FBA6875-219D-4B6E-9F34-BA3FA3BC4B13Q38373911-EC5B2F38-75BC-41C5-8410-7732CB66BBA2Q38510767-CC3C93BD-E52A-4B6F-8068-196A2A0C69A9Q38701038-90A5B1F2-0844-47BE-8345-7F7D0B83771FQ38799990-92BE1051-E790-48D9-93A2-F15E5AA7915EQ38826529-0E7C2240-0AA9-47AD-82C7-7B1281FF4793Q38961844-5E1C659D-0B4C-4700-8E4A-B6BFA3732B88Q39029981-DC5CC75A-2F9A-457A-9D28-AE3E2911BFF3Q39146357-F0B139A8-AA37-412F-AA2F-19F5C2F12D09Q39325636-AF6C6834-CA7C-40DE-82FF-412305F36A29Q39554981-CBF70A1C-4284-475A-8DCA-3D5D37FE7396
P2860
Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Counterbalance between RB inac ...... mage induction in lung cancers
@ast
Counterbalance between RB inac ...... mage induction in lung cancers
@en
Counterbalance between RB inac ...... mage induction in lung cancers
@nl
type
label
Counterbalance between RB inac ...... mage induction in lung cancers
@ast
Counterbalance between RB inac ...... mage induction in lung cancers
@en
Counterbalance between RB inac ...... mage induction in lung cancers
@nl
prefLabel
Counterbalance between RB inac ...... mage induction in lung cancers
@ast
Counterbalance between RB inac ...... mage induction in lung cancers
@en
Counterbalance between RB inac ...... mage induction in lung cancers
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Counterbalance between RB inac ...... mage induction in lung cancers
@en
P2093
T Yamaguchi
Y Matsuyama
P2860
P2888
P304
P3181
P356
10.1038/ONC.2009.201
P407
P577
2009-07-13T00:00:00Z
P5875
P6179
1037331347